These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28422287)

  • 1. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
    Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.
    Kap EJ; Seibold P; Richter S; Scherer D; Habermann N; Balavarca Y; Jansen L; Becker N; Pfütze K; Popanda O; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Pharmacogenomics J; 2015 Dec; 15(6):505-12. PubMed ID: 25778469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P; Labonte MJ; Lenz HJ
    Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
    Martinez-Balibrea E; Martínez-Cardús A; Ginés A; Ruiz de Porras V; Moutinho C; Layos L; Manzano JL; Bugés C; Bystrup S; Esteller M; Abad A
    Mol Cancer Ther; 2015 Aug; 14(8):1767-76. PubMed ID: 26184483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
    Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
    Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
    Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
    World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
    Iwatsuki M; Mimori K; Yokobori T; Tanaka F; Tahara K; Inoue H; Baba H; Mori M
    J Surg Oncol; 2009 Sep; 100(3):261-6. PubMed ID: 19330779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Kweekel DM; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
    Kap EJ; Popanda O; Chang-Claude J
    Pharmacogenomics; 2016 May; 17(7):755-94. PubMed ID: 27183147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
    Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
    J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
    Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.